Drug intelligence / Profile preview

THOR-211

Development stage: Preclinical
Lead developer: THOR Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

THOR-211 is a monoclonal antibody currently in preclinical development by THOR Biopharma. It is designed to target the RET (Rearranged during Transfection) receptor tyrosine kinase. RET signaling is frequently dysregulated in various cancers, including medullary thyroid cancer and non-small cell lung cancer (NSCLC), through mutations or chromosomal rearrangements. By binding to RET, THOR-211 is intended to block downstream signaling pathways that drive tumor growth and survival. The program is currently in the candidate optimization stage of preclinical development.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on THOR-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THOR-211.

Explore the full profile